Jiangsu Hengrui Pharma Delays Board Re-election, Extends Current Directors’ Terms

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.

Jiangsu Hengrui Pharmaceuticals has announced that the term of its ninth board of directors expired on 1 February 2026, but the planned re-election will be postponed while preparations are still underway. To ensure continuity and stability, the mandates of existing board members, board committees and senior management are being extended, and they will continue to perform their duties under relevant laws and the company’s articles of association. The company stressed that this delay will not disrupt normal operations and said it is expediting the necessary procedures to complete the board re-election and will update the market in line with disclosure rules, signalling an emphasis on governance continuity for stakeholders during the transition period.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company engaged in the research, development, manufacturing and sale of medicines, with its shares listed in both Shanghai and Hong Kong. The company operates in the broader healthcare and biotech industry, focusing on innovative therapies and prescription drugs for the domestic Chinese market and international investors through its H-share listing in Hong Kong.

Average Trading Volume: 3,237,278

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$432.1B

For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.